Your browser doesn't support javascript.
loading
Profound weight loss associated with reboxetine use in a 44-year-old woman.
Lu, T Y-T; Kupa, A; Easterbrook, G; Mangoni, A A.
Afiliación
  • Lu TY; Department of Clinical Pharmacology & Centre for Neuroscience, Flinders Medical Centre and Flinders University, Adelaide, Australia.
Br J Clin Pharmacol ; 60(2): 218-20, 2005 Aug.
Article en En | MEDLINE | ID: mdl-16042676
We report a case of significant weight loss experienced by a 44-year-old Caucasian woman treated with reboxetine. She was treated with this drug at 12 mg daily for a total duration of 11 months. During the corresponding period her body mass index (BMI) decreased from a baseline of 21.4 kg m(-2) to a low of 16.8 kg m(-2). Withdrawal of the drug led to a full recovery of her BMI. The strongest evidence linking reboxetine to this woman's weight loss laid in the fact that the re-introduction of the drug subsequently caused a similar negative impact in her BMI.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pérdida de Peso / Morfolinas / Inhibidores de Captación Adrenérgica / Antidepresivos Tipo de estudio: Risk_factors_studies Límite: Adult / Female / Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2005 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pérdida de Peso / Morfolinas / Inhibidores de Captación Adrenérgica / Antidepresivos Tipo de estudio: Risk_factors_studies Límite: Adult / Female / Humans Idioma: En Revista: Br J Clin Pharmacol Año: 2005 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Reino Unido